Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BridgeBio Pharma ( (BBIO) ) has shared an announcement.
On June 27, 2025, BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. Eidos sold certain royalty rights on net sales of products containing acoramidis in the EU to the purchasers for $300 million. This agreement provides BridgeBio with immediate capital while capping the purchasers’ royalty rights and offering security interests in specific assets, potentially impacting the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a biotechnology company that focuses on developing transformative medicines to treat genetic diseases. Its subsidiary, Eidos Therapeutics, Inc., is involved in creating therapies for rare diseases, with a market focus on genetic conditions.
Average Trading Volume: 3,166,150
Technical Sentiment Signal: Buy
Current Market Cap: $8.12B
See more insights into BBIO stock on TipRanks’ Stock Analysis page.